Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

  1. Home
  2. /Clinical
  3. /Phase II

Clinical

Phase II(11)

Follow pivotal data releases and trial developments that create new strategic pressure for biotech and pharma operators.

11 signals

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.

ScoreIntelligence Record
7.0

CLINICAL

Phase II Trial Investigates Vitamin D's Impact on Menstrual Cycle Health

The inVitD Trial aims to assess the effects of vitamin D supplementation on menstrual cycle hormones in women aged 19-40.

Fertility·Women's Health·June 18, 2026
7.0

CLINICAL

Zilovertamab Vedotin Shows Promise in rrDLBCL with Standard Care in Phase 2/3 Study

A Phase 2/3 study is evaluating zilovertamab vedotin in combination with standard care for rrDLBCL, with a protocol amendment discontinuing enrollment in one cohort.

Merck·Oncology·June 17, 2026
7.0

CLINICAL

Phase 2 Study of AUR103 Calcium in Advanced Neuroendocrine Tumours Initiated

AUR103 calcium is being evaluated in Phase 2 study for efficacy and safety in advanced neuroendocrine tumors.

AUR103 Pharma·Oncology·June 17, 2026
7.0

CLINICAL

Study Evaluates Outcomes After Discontinuation of BTK Inhibitors in CLL Patients

A Phase II study is assessing the outcomes of stopping BTK inhibitor therapy in CLL patients in remission for over two years.

AbbVie·Ibrutinib·June 17, 2026
7.0

CLINICAL

Phase II Trial Compares FOLFOX8 and mFOLFOX6 in Metastatic Colorectal Cancer

A phase II trial is underway to compare the efficacy and safety of FOLFOX8 versus mFOLFOX6 with bevacizumab or cetuximab in patients with unresectable metastatic colorectal cancer.

Roche·FOLFOX8·June 17, 2026
8.0

CLINICAL

CMP-001 and Nivolumab Show Promise in Advanced Melanoma Phase 2/3 Trial

A Phase 2/3 study is evaluating CMP-001 in combination with nivolumab against nivolumab monotherapy in advanced melanoma.

Regeneron·CMP-001·June 16, 2026
7.0

CLINICAL

Roche to Present Phase II Data on Enicepatide and Petrelintide at ADA 2026

Roche will present new Phase II data for enicepatide and petrelintide in obesity at the ADA Scientific Sessions.

Roche·obesity·June 16, 2026
7.0

COMPETITIVE

Roche to Present Phase II Data on Enicepatide and Petrelintide at ADA 2026

Roche will present new data from the Phase II studies of enicepatide and petrelintide in obesity at the ADA Scientific Sessions.

Roche·Obesity · Peptide Therapy·June 16, 2026
8.0

COMPETITIVE

Roche Advances Obesity Portfolio with Promising Phase II Data on Enicepatide and Petrelintide

Roche presented late-breaking Phase II data showing significant efficacy and safety for enicepatide and petrelintide in weight management.

Roche·Enicepatide·June 16, 2026
7.0

CLINICAL

Phase II Trial of SAL0140 Shows Promise for Primary Aldosteronism

A Phase II clinical trial is underway to evaluate the efficacy and safety of SAL0140 at varying doses in patients with primary aldosteronism.

SAL0140·primary aldosteronism market·June 13, 2026
7.0

CLINICAL

Phase II Trial of Venetoclax and Rituximab in Older Patients With Mantle Cell Lymphoma

A Phase II trial is underway to evaluate the efficacy of venetoclax combined with rituximab in older patients with untreated mantle cell lymphoma.

Venetoclax·Rituximab·June 10, 2026

Showing 1–11 of 11 records